



NC DEPARTMENT OF
**HEALTH AND
HUMAN SERVICES**

JOSH STEIN • Governor

DEVDDUTTA SANGVAL • Secretary

KELLY KIMPLE • Acting Director, Public Health

July 15, 2025

MEMORANDUM

TO: Vaccines for Children Program (VFC) Participants

FROM: Beth Meadows, MSN, RN, CPHN *BM*
Provider Clinical Services Unit Lead
Interim Immunization Branch Director

SUBJECT: Respiratory Syncytial Virus (RSV) Vaccine Available for Ordering

The purpose of this memo is to provide VFC- enrolled providers with information on ordering timelines and administration start dates for the maternal RSV vaccine (**ABRYSVO®**) and the monoclonal antibody nirsevimab (**Beyfortus®**) for the upcoming season.

Although ordering will open before the administration period, **providers should not begin administering RSV products until the Centers for Disease Control and Prevention's (CDC) official administration start dates.**

In addition, **Clesrovimab (ENFLONISIA™)** was approved at the June Advisory Committee on Immunization Practices (ACIP) meeting as another RSV prevention option for infants. Implementation guidance is still pending, and we will provide updates as soon as they become available.

Administration Timing

ABRYSVO® is recommended for pregnant individuals (who have not previously been vaccinated with ABRYSVO®) at 32 through 36 weeks gestation to protect infants from RSV-related lower respiratory tract infections in their first 6 months of life.

Beyfortus® is recommended for infants younger than 8 months of age who are born during or are entering their first RSV season as well as for some children (ages 8 through 19 months) who

NC DEPARTMENT OF HEALTH AND HUMAN SERVICES • DIVISION OF PUBLIC HEALTH

LOCATION: 5605 Six Forks Road, Building 3, Raleigh, NC 27609
MAILING ADDRESS: 1931 Mail Service Center, Raleigh, NC 27699-1931
www.ncdhhs.gov • TEL: 919-707-5000 • FAX: 919-870-4829

AN EQUAL OPPORTUNITY / AFFIRMATIVE ACTION EMPLOYER

are at increased risk for severe RSV disease and entering their second RSV season. This monoclonal antibody provides immediate protection against RSV and lasts at least 5 months.

Most infants will need protection from either maternal RSV vaccination or infant immunization, but not both. However, in some cases, such as when a baby is born less than two weeks after maternal immunization, Beyfortus® would also be recommended.

The timing of both products is seasonal. Providers should follow CDC's recommended start and end dates for RSV product administration during the 2025–26 season:

- **ABRYSVO®**: September 1, 2025 – January 31, 2026
- **Beyfortus®**: October 1, 2025 – March 31, 2026

Ordering Information

To ensure equitable distribution of VFC doses, NCDHHS will utilize the [RSV Order Request Form](#) to fill Beyfortus®, ABRYSVO®, and future RSV products order requests.

Details Ordering

Initial ordering and shipping for Beyfortus® will open on **August 1, 2025**. **ABRYSVO®** is currently **available for order**. Submit an order request for VFC doses to cover the first two week period of RSV season using the [RSV Order Request Form](#). All requests will be reviewed and approved on a biweekly cadence. Orders will be cut off and reviewed at 9:00 am every other Monday.

Ordering Considerations

- NCDHHS will review orders to ensure equitable distribution. Examples of data reviewed include geographic location, doses administered, and current inventory.
- VFC providers should consider the number of VFC doses used in a two-week period, along with the number of VFC doses in their current inventory, to determine the amount to request.
- Doses obtained from NCIP are for VFC-eligible patients only. Privately purchased stock must be used for fully insured patients.

Clinical information, including product indications and dosing guidance, remains consistent with last year's recommendations and can be found in the [2024 RSV Clinical Memo link](#).

How to contact us:

For assistance, please contact the NCIR Help Desk by phone: 1.877.USE.NCIR (873-6247) or by [email](#).

Thank you for your ongoing partnership and dedication to improving immunization outcomes in North Carolina.

In Health,
NC Department of Health and Human Services